Recent studies have demonstrated that Nrf2 is found hyper-activated in malignant cells with gain of function mutations resulting in survival advantages to cancer cells because the same cytoprotective genes can favour tumour growth and metastasis. This evidence concerns the gene NFE2L2 and neoplasm.